Search Results - technology+classifications+%3e+life+sciences+%3e+small+molecules

56 Results

Sort By:

nsP2 Inhibitors: Targeting the Alphavirus nsP2 Protease

This invention relates to antiviral compounds targeting the alphavirus nsP2 protease, pharmaceutical compositions, and methods of use for the prevention, treatment, or mitigation of the Chikungunya virus. This compound selectively interferes with the essential proteolytic processing activity of nsP2, a critical step in the viral life cycle. By blocking...

Published: 4/29/2026 | Updated: 4/29/2026 | Inventor(s): Hongmin Li, Rui Xiong, Subodh Samrat, Malla Reddy Gannarapu, Ran Zhang, Ke Chen, Mengjiao Ma, Omar Alejandro Lozano Ramos, Divakar Indukuri, Renu Bhardwaj

Keywords(s):

Category(s): Technology Classifications > Healthcare Portfolios > Infectious Diseases, Technology Classifications > Life Sciences > Therapeutics, Technology Classifications > Life Sciences > Small Molecules

Therapeutic Target of Ewing Sarcoma by G-Quadruplex Binding Compound

This innovation identified lead molecules that target specific nucleic acid structures involved with forming G-Quadruplex structures. These G-Quadruplex structures are a highly stable nucleic acid fold with planar stacks of guanine tetrads which regulate genome stability, transcription, and telomere maintenance. This innovation details a therapeutic...

Published: 3/12/2026 | Updated: 1/6/2026 | Inventor(s): Jacob Schwartz, Haining Zhu, Ajibola Adelekun, Valery Thompson

Keywords(s):

Category(s): Technology Classifications > Life Sciences > Small Molecules, Technology Classifications > Life Sciences > Therapeutics, Technology Classifications > Healthcare Portfolios > Oncology

Novel Mechanism-Based Therapy for Aortic Stiffening and Related Cardiovascular and Cerebrovascular Disorders

This invention involves a novel mechanism-based therapy by using a small molecule compound to reduce aging and hypertensive aortic stiffening, subsequently improve blood pressure (BP) control in resistant hypertension patients and prevent or reverse pathologies of vascular cognitive impairment and dementia (VCID) and Alzheimer’s Disease (AD)....

Published: 11/24/2025 | Updated: 11/24/2025 | Inventor(s): Hongyu Qiu

Keywords(s):

Category(s): Technology Classifications > Healthcare Portfolios > Heart and Vascular, Technology Classifications > Healthcare Portfolios > Neurology, Technology Classifications > Life Sciences > Small Molecules, Technology Classifications > Life Sciences > Therapeutics

Lasmiditan as a Treatment for Organ Transplant Rejection

Lasmiditan is a drug currently used to treat migraines. However, University of Arizona researchers discovered that Lasmiditan induces mitochondrial biogenesis in mouse kidneys and restores renal function to mice subjected to kidney injury. Mitochondria have been identified as important therapeutic targets in the aftermath of organ transplantation. This...

Published: 2/23/2026 | Updated: 10/2/2025 | Inventor(s): Rick Schnellmann, Bekir Tanriover

Keywords(s):

Category(s): Technology Classifications > Life Sciences > Small Molecules, Technology Classifications > Healthcare Portfolios > Transplantation

CD64+ AND CD14+ Cell Replacement Therapy for Wound Healing

This technology is a cell-based therapy involving an administered dose of cells expressing both CD64+ and CD14+ ligands. It is designed to promote healing in diabetic patients, with potential to reduce inflammation and support tissue regeneration. The cells can be observed in tissue, blood, and bone marrow, allowing for broader variety in addressing...

Published: 3/18/2026 | Updated: 9/15/2025 | Inventor(s): Geoffrey Gurtner, Kellen Chen, Katharina Berryman, Maria Gracia Mora Pinos

Keywords(s):

Category(s): Technology Classifications > Healthcare Portfolios > Diabetes, Metabolism, Endocrinology & Obesity, Technology Classifications > Healthcare Portfolios > Immunology, Autoimmune & Inflammation, Technology Classifications > Life Sciences > Small Molecules, Technology Classifications > Life Sciences > Therapeutics

Modifying the Gastric Tumor Microenvironment with Tadalafil

This technology leverages phosphodiesterase 5 (PDE5) inhibitors—such as tadalafil and sildenafil—in combination with the standard of care to treat gastric adenocarcinomas (GAC). The use of PDE5 inhibitors has the potential to enhance immune response and treatment outcomes with a well-established safety profile. Background: Gastric adenocarcinoma...

Published: 9/2/2025 | Updated: 9/2/2025 | Inventor(s): Juanita Merchant

Keywords(s):

Category(s): Technology Classifications > Healthcare Portfolios > Gastroenterology Disease, Technology Classifications > Healthcare Portfolios > Oncology, Technology Classifications > Life Sciences > Small Molecules, Technology Classifications > Life Sciences > Therapeutics

DHODH Inhibitors

This technology includes novel compounds that selectively inhibit fungal dihydroorotate dehydrogenase (DHODH), an essential enzyme in pyrimidine biosynthesis. These inhibitors are active against a range of fungal pathogens, including Cryptococcus neoformans and Candida auris, while sparing the human version of the enzyme. This selectivity reduces the...

Published: 8/18/2025 | Updated: 8/18/2025 | Inventor(s): Hongmin Li, Anil Tharappel, Zhong Li

Keywords(s):

Category(s): Technology Classifications > Healthcare Portfolios > Infectious Diseases, Technology Classifications > Life Sciences > Small Molecules

Preparation of Apomorphine and its Analogs for Neurodegenerative Disease Applications

This invention involves methods of apomorphine synthesis from different starting blocks to facilitate more robust drug development campaigns by enabling chemical substitutions at unexplored locations. It includes total synthesis of apomorphine from readily available fragments and whose synthetic design approach centers around being maximally amenable...

Published: 8/11/2025 | Updated: 8/11/2025 | Inventor(s): Jon Njardarson, Nicholas Lauta

Keywords(s):

Category(s): Technology Classifications > Healthcare Portfolios > Neurology > CNS & Neurosciences, Technology Classifications > Life Sciences > Drug Delivery, Technology Classifications > Life Sciences > Small Molecules, Technology Classifications > Life Sciences > Therapeutics, Technology Classifications > Research Tools > Reagents, Technology Classifications > Veterinary Medicine > Therapeutics & Vaccines

Barettin Analogs

This invention features a novel barettin analogs, which are designed for the treatment of tuberculosis (TB) and chronic pain. Barettin, a naturally derived marine compound, has shown promising biological activity, and these synthetic analogs are optimized to enhance therapeutic effects while minimizing potential side effects. The innovation aims to...

Published: 6/30/2025 | Updated: 6/30/2025 | Inventor(s): Christopher Cartmell, Michael Okine, John Streicher, Caleb Seekins

Keywords(s):

New Therapeutic Strategy for Pancreatic Cancer with Wnt Inhibitors from Phenoxazine Derivatives

This invention is for a novel small molecule therapy for the treatment of Pancreatic ductal adenocarcinoma (PDAC). This new set of compounds contain inhibitors that have shown successfully slowed tumor progression by reducing expression of two major tumor-causing mutated oncoproteins in mouse models. Background: Pancreatic ductal adenocarcinoma (PDAC)...

Published: 3/24/2025 | Updated: 3/24/2025 | Inventor(s): Daekyu Sun

Keywords(s):

Category(s): Technology Classifications > Healthcare Portfolios > Oncology, Technology Classifications > Life Sciences > Small Molecules

1 2 3 4 5 6